Unconventional vaccines: Progress and challenges

Journal of Vaccines and Vaccination

Volumn 4, Issue 4, 2013, Pages 186-

  Petrovsky, Nikolai ^a,b  

^a VAXINE PTY LTD   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Immunogenicity; Infectious diseases; Vaccines

Indexed keywords

EID: 84879931604     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000186     Document Type: Review

References (44)

1. Berzofsky JA, Terabe M, Wood LV (2012) Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol 39: 348-357.
2. Papadopoulos NG, Agache I, Bavbek S, Bilo BM, Braido F, et al. (2012) Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clin Transl Allergy 2: 21.
3. Bachmann MF, Jennings GT (2011) Therapeutic vaccines for chronic diseases: successes and technical challenges. Philos Trans R Soc Lond B Biol Sci 366: 2815-2822.
4. Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, et al. (2012) Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. Int Braz J Urol 38: 717-727.
5. Ogi C, Aruga A (2013) Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother 9.
6. Brusic V, Petrovsky N, Gendel SM, Millot M, Gigonzac O, et al. (2003) Computational tools for the study of allergens. Allergy 58: 1083-1092.
7. Baldrick P, Richardson D, Woroniecki SR, Lees B (2007) Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J Appl Toxicol 27: 399-409.
8. Rosewich M, Lee D, Zielen S (2013) Pollinex Quattro: An innovative four injections immunotherapy In allergic rhinitis. Hum Vaccin Immunother 9.
9. Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, et al. (2011) Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 41: 1305-1312.
10. Thatte U (2001) AN-1792 (Elan). Curr Opin Investig Drugs 2: 663-667.
11. Robinson SR, Bishop GM, Lee HG, Münch G (2004) Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 25: 609-615.
12. Ryan JM, Grundman M (2009) Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 17: 243.
13. 2 immunotherapy CAD106 passes first safety test in patients with Alzheimer disease. Nat Rev Neurol 8: 414.
14. 2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11: 597-604.
15. 2 immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31: 9323-9331.
16. Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, et al. (2009) Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. J Nutr Health Aging 13: 264-267.
17. Hutter-Saunders JA, Mosley RL, Gendelman HE (2011) Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother 11: 1703-1715.
18. Affiris AG (2013) Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease.
19. Komori T (2004) CETi-1. AVANT. Curr Opin Investig Drugs 5: 334-338.
20. Affiris AG (2012) Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP).
21. Allas S, Abribat T (2013) Clinical perspectives for ghrelin-derived therapeutic products. Endocr Dev 25: 157-166.
22. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, et al. (2004) Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 107: 167-173.
23. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, et al. (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25: 63-72.
24. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, et al. (2008) Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827.
25. Hellings N, Stinissen P (2008) Tovaxin, radiation-attenuated, patient-specific T-cells for the therapeutic vaccination of multiple sclerosis. Curr Opin Investig Drugs 9: 534-540.
26. Spohn G, Guler R, Johansen P, Keller I, Jacobs M, et al. (2007) A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178: 7450-7457.
27. Ludvigsson J (2010) GAD-alum (Diamyd)--a new concept for preservation of residual insulin secretion. Expert Opin Biol Ther 10: 787-799.
28. Hinke SA (2008) Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Curr Opin Mol Ther 10: 516-525.
29. (2011) DIAPREV-IT study of diabetes therapy Diamyd® receives further funding and will continue despite disappointing Phase III trial results. Immunotherapy 3: 923-924.
30. Lernmark A, Larsson HE (2013) Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol 9: 92-103.
31. Faustman DL, Wang L, Okubo Y, Burger D, Ban L, et al. (2012) Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One 7: e41756.
32. Silva DG, Charlton B, Cowden W, Petrovsky N (2003) Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen. Ann N Y Acad Sci 1005: 423-430.
33. Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, Brauer R, et al. (2012) The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 12: 1052.
34. Heading CE (2003) NicVAX (Nabi Biopharmaceuticals). IDrugs 6: 1178-1181.
35. Novartis (2009) Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of 100μg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.
36. Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031-2040.
37. Heading CE (2002) TA-CD. Xenova. IDrugs 5: 1070-1074.
38. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82: 488-496.
39. Nikolai Petrovsky, Susanne Heinzel, Yoshikazu Honda, A. Bruce Lyons (2007) New-Age Vaccine Adjuvants: Friend or Foe? Biopharm International 20: 24-33.
40. 2-D-[2-> 1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology 21: 595-606.
41. Petrovsky N, Cooper PD (2011) Carbohydrate-based immune adjuvants. Expert Rev Vaccines 10: 523-537.
42. Honda-Okubo Y, Saade F, Petrovsky N (2012) Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30: 5373-5381.
43. Saade F, Honda-Okubo Y, Trec S, Petrovsky N (2013) A novel hepatitis B vaccine containing Advaxâ"¢, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31: 1999-2007.
44. Petrovsky N (2008) Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines 7: 7-10.